

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_76608
Title of the Manuscript:	Angiopoietin-like protein 3 AND Cardiovascular Disease: A Mini REVIEW
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Abstract Part:</p> <p>i. Author should replace writing all the word study to review as “The review is aimed...”.</p> <p>ii. In line 2: replace “...lipid levels in type 2 diabetics.... “ with “ ...lipid levels in diabetes mellitus type 2 (T2DM).”</p> <p>iii. In line 4: add the basic form of CVD as follow “Cardiovascular Disease (CVD)...”</p> <p>iv. Author should write the basic word follow its abbreviation in the first position “ ... expressions of Angiopietin-like protein 3 (ANGPTL3), LDL receptor and apoB100 ...”</p> <p>v. What does it mean in scientific expression...”....thereby contributing to the risk of CVD in diabetes is the need for the hour.”...</p>	
Minor REVISION comments	<ul style="list-style-type: none">• Part DM AND CVD RISK: <p>Author could change title of this part : Overlapping between diabetes and hyperlipidemia</p> <ul style="list-style-type: none">• Part ANGPTL3 AND DM: <p>Author could change title of this part: Correlation between insulin sensitivity and angiotietin-like protein 3</p> <ul style="list-style-type: none">• Part ANGPTL3 and CVD & part ANGPTL3 and Lipid profile : <p>Author could merge those two titles to one title: for example “The effect of Angiotietin-like protein3 on lipid profile and Cardiovascular Disease”</p> <p>AS well as, rearrange the second paragraph to be in the first “Angiotietin-like protein3 has been considered astill LDL-C remains unclear[17].</p> <p>Then, put the paragraph which started with “ANGPTL3 is an endogenous inhibitor till.... risk of CVD in Caucasians [8-10].</p>	
Optional/General comments	<p>Part Keywords : Angiotietin-like protein3, liver X receptor, hyperlipidemia, T2DM , gene treatment</p>	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Asmaa Ahmed Salem
Department, University & Country	Agricultural Research Center (ARC), Egypt